- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02618720
Intravenous Versus Combined Oral and Intravenous Antimicrobial Prophylaxis for the Prevention of Surgical Site Infection in Elective Colorectal Surgery (COMBINE)
Intravenous Versus Combined Oral and Intravenous Antimicrobial Prophylaxis for the Prevention of Surgical Site Infection in Elective Colorectal Surgery: A Double-blinded Multicenter Prospective Randomized Controlled Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Surgical site infection (SSI) is a major cause of nosocomial infection in surgical patients, with the highest rates being reported (ranging from 15% to 30%) in colorectal surgery. SSI is an independent predictor of postoperative mortality and is associated with longer hospital stay, a 5-fold likelihood of postoperative readmission and a 2- to 3-fold increase in costs of care. Given the high prevalence and financial burden associated with SSI, American and European guidelines have been issued providing evidenced-based recommendations for the prevention of postoperative SSI. However, the prevalence of SSI remains high despite adherence to these guidelines and the application of evidence-based preventive measures.
Risk factors for SSI, whether modifiable or not, are mainly related to the patient condition (including age, severe comorbidity, diabetes, nutritional status, steroid use, smoking, and immunosuppression) and/or the surgical procedure (especially the surgical duration and skin disinfection). The prevention of SSI consists of several individual measures, and antibiotic prophylaxis covering aerobic and anaerobic bacteria is highly recommended in patients scheduled to elective colorectal resection, with French and European guidelines recommending the administration of intravenous cephalosporin within 30 minutes before surgical incision.
Recent data from retrospective studies and two meta-analyses of clinical trials provided compelling arguments that oral antibiotic administration before surgery in addition to conventional intravenous prophylaxis may be useful in further reducing by almost 75% the incidence of SSI (relative risk 0.55 [CI95%: 0.41 to 0.74]) after elective colorectal cancer surgery.
However, most of these studies have limitations precluding extrapolation of data into routine care, especially:
- prolonged duration of intravenous antibiotic administration, which is no longer recommended in elective surgery;
- the use of antibiotics for oral prophylaxis whose availability is limited;
- only a few studies focused specifically on colorectal resection;
- most studies did not include enhanced recovery after surgery (ERAS) programs, which was found to improve outcome following colorectal surgery, and
- most studies have used mechanical bowel preparation, which is no longer recommended in colonic surgery while the issue still remains open for rectal surgery.
Investigators hypothesized that oral antibiotic prophylaxis using ornidazole, which has a spectrum of activity extended to most anaerobic bacteria and whose pharmacokinetic profile allows a single administration the day before surgery, in addition to intravenous antibiotic prophylaxis could be more effective than intravenous antibiotic prophylaxis alone using cephalosporin in reducing the incidence of SSI after elective colorectal surgery. Given the number of patients operated of colorectal surgery each year, the study is of significant clinical importance
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Clermont-Ferrand, France, 63003
- Chu Clermont-Ferrand
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age > 18
- Laparoscopic or non-laparoscopic elective colorectal surgery
Exclusion Criteria:
- Non elective colorectal surgery (emergent surgery and/or reintervention or revision of a previous colorectal procedure)
- Significant concomitant surgical procedure (e.g., liver resection for metastasis)
- Bacterial infection at the time of surgery or antimicrobial therapy up to 2 weeks before surgery
- Inflammatory bowel disease
- Severe obesity (defined as a BMI >35 kg/m2)
- Known history of hypersensitivity to β-lactams and imidazoles
- Preoperative severe impairment in renal function (creatinine clearance (MDRD) < 30 ml/min)
- Patients with known colonization with multidrug-resistant digestive bacteria, especially multidrug-resistant gram-negative bacteria (requiring specific infection control measures)
- Allergy to lactose, galactose intolerance, Lapp lactase deficiency or glucose/galactose malabsorption (rare metabolic disease)
- Pregnant women, breastfeeding women, women of childbearing age without effective contraceptive- Refusal to participate or inability to provide informed consent
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: ornidazole
oral antibiotic prophylaxis using ornidazole, which has a spectrum of activity extended to most anaerobic bacteria and whose pharmacokinetic profile allows a single administration the day before surgery, in addition to intravenous antibiotic prophylaxis could be more effective than intravenous antibiotic prophylaxis alone using cephalosporin in reducing the incidence of SSI after elective colorectal surgery.
Given the number of patients operated of colorectal surgery each year, the study is of significant clinical importance
|
|
Placebo Comparator: placebo
oral antibiotic prophylaxis using ornidazole, which has a spectrum of activity extended to most anaerobic bacteria and whose pharmacokinetic profile allows a single administration the day before surgery, in addition to intravenous antibiotic prophylaxis could be more effective than intravenous antibiotic prophylaxis alone using cephalosporin in reducing the incidence of SSI after elective colorectal surgery.
Given the number of patients operated of colorectal surgery each year, the study is of significant clinical importance
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
occurrence of any SSI within 30 days after surgery.
Time Frame: 30 days after surgery
|
The primary end point of the trial is the occurrence of any SSI within 30 days after surgery.
SSI will be classified as superficial, deep and/or organ-space infection according to validated and well-defined criteria developed by the Centers for Disease Control and Prevention (CDC).
|
30 days after surgery
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of individual types of SSI according to the group of treatment
Time Frame: 30 days after surgery
|
Incidence of individual types of SSI (superficial incision infection, deep incision infection and organ-space infection) according to the group of treatment, 30 days after surgery
|
30 days after surgery
|
Number of postoperative complications
Time Frame: 30 days after surgery
|
Using the Dindo and Clavien classification
|
30 days after surgery
|
Number of surgical complications: anastomotic leakage and the need for abdominal reoperation and/or radiological intervention
Time Frame: 30 days after surgery
|
30 days after surgery
|
|
Duration of hospital stay
Time Frame: 30 days after surgery
|
Including hospital stay of patients who are readmitted after surgery
|
30 days after surgery
|
All-cause mortality
Time Frame: 30 days after surgery
|
30 days after surgery
|
|
All-cause mortality
Time Frame: 90 days after surgery
|
90 days after surgery
|
|
Time to introduction of adjuvant chemotherapy related to SSI
Time Frame: 30 days after surgery
|
30 days after surgery
|
|
Postoperative syndrome of systemic inflammatory response (Infectious complications)
Time Frame: 30 days after surgery
|
Number of Postoperative syndrome of systemic inflammatory responses, in each group
|
30 days after surgery
|
Sepsis (Infectious complications)
Time Frame: 30 days after surgery
|
Number of Sepsis, in each group
|
30 days after surgery
|
Septic shock (Infectious complications)
Time Frame: 30 days after surgery
|
Number of Septic shocks, in each group
|
30 days after surgery
|
Arrhythmia (Cardiovascular complications)
Time Frame: 30 days after surgery
|
Number of arrhythmias, in each group
|
30 days after surgery
|
Myocardial infarction (Cardiovascular complications)
Time Frame: 30 days after surgery
|
Number of myocardial infarctions, in each group
|
30 days after surgery
|
Acute cardiac failure (Cardiovascular complications)
Time Frame: 30 days after surgery
|
Number of acute cardiac failures, in each group
|
30 days after surgery
|
Pneumonia (Respiratory complications)
Time Frame: 30 days after surgery
|
Number of pneumonias, in each group
|
30 days after surgery
|
Need for postoperative reventilation (Respiratory complications)
Time Frame: 30 days after surgery
|
Number of postoperative reventilations (intubation and/or non-invasive mechanical ventilation), in each group
|
30 days after surgery
|
Renal dysfunction
Time Frame: 30 days after surgery
|
Number of Renal dysfunctions in each group.
Defined according to the Kidney Disease: Improving Global Outcomes (KDIGO) classification
|
30 days after surgery
|
Time to initiation of adjuvant chemotherapy
Time Frame: 30 days after surgery
|
Comparaison of time to initiation of adjuvant chemotherapy between the 2 groups
|
30 days after surgery
|
Need for hospital readmission
Time Frame: 30 days after surgery
|
Number of hospital readmissions, in each group
|
30 days after surgery
|
Unexpected admission to intensive care unit
Time Frame: 30 days after surgery
|
Number of Unexpected admissions to intensive care unit, in each group
|
30 days after surgery
|
Hospital free days
Time Frame: 30 days after surgery
|
30 days after surgery
|
Collaborators and Investigators
Publications and helpful links
General Publications
- Futier E, Jaber S, Garot M, Vignaud M, Panis Y, Slim K, Lucet JC, Lebuffe G, Ouattara A, El Amine Y, Couderc P, Dupre A, De Jong A, Lasocki S, Leone M, Pottecher J, Pereira B, Paugam-Burtz C; COMBINE study group. Effect of oral antimicrobial prophylaxis on surgical site infection after elective colorectal surgery: multicentre, randomised, double blind, placebo controlled trial. BMJ. 2022 Nov 3;379:e071476. doi: 10.1136/bmj-2022-071476.
- Vignaud M, Paugam-Burtz C, Garot M, Jaber S, Slim K, Panis Y, Lucet JC, Bourdier J, Morand D, Pereira B, Futier E; COMBINE trial management committee. Comparison of intravenous versus combined oral and intravenous antimicrobial prophylaxis (COMBINE) for the prevention of surgical site infection in elective colorectal surgery: study protocol for a multicentre, double-blind, randomised controlled clinical trial. BMJ Open. 2018 Apr 12;8(4):e020254. doi: 10.1136/bmjopen-2017-020254.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CHU-0250
- 2015-002559-84 (Registry Identifier: 2015-002559-84)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Elective Colorectal Surgery
-
Centre Hospitalier Universitaire DijonTerminatedElective Colorectal SurgeryFrance
-
Centre Hospitalier Universitaire, AmiensCentre Hospitalier de BeauvaisActive, not recruiting
-
University Hospital MuensterInternational Anesthesia Research Society (IARS)TerminatedColorectal Surgery | Elective Surgical ProcedureGermany
-
Tongji HospitalNot yet recruiting
-
Washington University School of MedicineCompletedElective SurgeryUnited States
-
Rigshospitalet, DenmarkCompleted
-
Nanjing Medical UniversityCompleted
-
Nanjing Medical UniversityCompleted
-
Duke UniversityCompleted
-
AbbottRundo International Pharmaceutical Research & Development Co.,Ltd.Completed
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States